Tirzepatide vs Semaglutide: Which Is Better for Weight Loss?

Tirzepatide (sold as Zepbound and Mounjaro) and semaglutide (sold as Wegovy and Ozempic) are both prescription injections approved by the FDA for chronic weight management at higher doses. In the largest head-to-head trial completed so far, tirzepatide produced greater average weight loss than semaglutide: about 20.2% of body weight versus 13.7% over 72 weeks. That does not make tirzepatide automatically better for every person, because tolerance, price, and insurance coverage often decide the real-world answer.

When people search for tirzepatide vs semaglutide which is better for weight loss, they usually want one number that settles the argument. The published data favors tirzepatide on average, but an average hides a wide range of individual results.

The Short Answer: Which One Comes Out Ahead?

Tirzepatide has the stronger average weight-loss results in direct comparison. Semaglutide has the longer track record, broader insurance coverage, and a lower list price at most US pharmacies.

• Tirzepatide produced greater average weight loss than semaglutide in the SURMOUNT-5 head-to-head trial.
• Both drugs are FDA-approved for chronic weight management, and neither is a cure for obesity.
• Their side effect profiles are similar, and most gastrointestinal symptoms ease during dose titration.
• Compounded versions of either drug are not FDA-approved and can vary in strength and purity.

Feature	Tirzepatide	Semaglutide
Mechanism	Dual GIP and GLP-1 receptor agonist	GLP-1 receptor agonist
Weight-loss brand name	Zepbound	Wegovy
Average weight loss, head-to-head trial (72 weeks)	About 20.2%	About 13.7%
Typical maintenance dose	5 mg to 15 mg weekly	1.7 mg to 2.4 mg weekly
Common side effects	Nausea, diarrhea, constipation, vomiting	Nausea, diarrhea, constipation, vomiting
FDA approved for weight management	Yes, since 2023	Yes, since 2021

How Tirzepatide and Semaglutide Work Differently

Semaglutide activates one gut hormone receptor: GLP-1. That receptor slows stomach emptying, signals fullness to the brain, and improves blood sugar control.

Tirzepatide activates two receptors: GIP and GLP-1. Researchers believe the added GIP activity improves insulin handling and may slightly reduce nausea at comparable weight-loss doses, although that advantage is not firmly proven.

Neither medication burns fat directly. They work by lowering appetite and calorie intake, which is why nutrition and activity still shape results. Search interest in semaglutide vs tirzepatide weight loss often comes from people reading real-world stories online rather than trial data, and those stories vary enormously.

Weight Loss Results: What the Trials Show

The STEP and SURMOUNT trial programs are the two largest bodies of evidence behind these medications. Semaglutide 2.4 mg produced roughly 14.9% average weight loss over 68 weeks in STEP 1, while tirzepatide 15 mg produced about 20.9% over 72 weeks in SURMOUNT-1.

SURMOUNT-5 put the two drugs head to head in adults with obesity but without diabetes. Roughly one in five tirzepatide participants lost at least 30% of body weight, compared with about one in twelve on semaglutide.

Trial	Drug and dose	Duration	Average weight loss
STEP 1	Semaglutide 2.4 mg	68 weeks	About 14.9%
SURMOUNT-1	Tirzepatide 15 mg	72 weeks	About 20.9%
SURMOUNT-5	Tirzepatide vs semaglutide 2.4 mg	72 weeks	20.2% vs 13.7%

One caveat matters: trial participants received regular check-ins, dietitian support, and structured dose escalation that most people do not get in routine care.

Side Effects, Hair Loss, and Tolerability

Both drugs cause similar gastrointestinal side effects, including nausea, vomiting, diarrhea, constipation, and burping. Symptoms are usually worst in the first four to eight weeks and after each dose increase.

Hair shedding is a frequent complaint. Rapid weight loss itself can trigger telogen effluvium, a temporary shedding phase, and the same pattern appears in discussions about tirzepatide vs semaglutide hair loss. Nutrient shortfalls from eating much less can make shedding worse.

Serious but uncommon risks include pancreatitis, gallbladder disease, and bowel obstruction. Both medications carry a boxed warning about thyroid C-cell tumors observed in rodents and should not be used with a personal or family history of medullary thyroid cancer or MEN2.

Talk with a healthcare professional before starting either drug or combining it with insulin or sulfonylureas.

Dosage, Titration, and Common Forum Questions

Both medications start low and increase about every four weeks to limit side effects.

Drug	Starting dose	Escalation	Maximum weekly dose
Tirzepatide (Zepbound)	2.5 mg	Every 4 weeks	15 mg
Semaglutide (Wegovy)	0.25 mg	Every 4 weeks	2.4 mg

Interest in tirzepatide vs semaglutide dosage reddit is high because people want to know whether a slower ramp reduces nausea. A gentler titration is a strategy some clinicians approve, but the FDA schedules exist for a reason and should be changed only with medical guidance.

Do not split doses, double up after a missed week, or buy unverified vials from social media sellers.

Cost, Compounded Versions, and Insurance Coverage

List prices for brand-name products exceed $1,000 per month in the United States before insurance or savings programs. Coverage varies by plan, and many insurers still require prior authorization or a trial of semaglutide first.

Compounded semaglutide and compounded tirzepatide grew popular during supply shortages. If you are asking what is the difference between semaglutide and tirzepatide compound, the short answer is that compounded products copy the active ingredient but are not FDA-approved, are not reviewed for purity, and can differ in concentration from the brand versions.

The FDA has cautioned against compounded versions when approved alternatives are available.

How to Choose With Your Doctor

There is no single winner for every patient. Bring these questions to your next appointment:

1. Does my insurance cover tirzepatide, semaglutide, or both?
2. Do I have diabetes, kidney disease, or a history of pancreatitis that shifts the risk-benefit balance?
3. How much weight loss would meaningfully improve my health, and how quickly do I need it?
4. What is the plan if I cannot tolerate the starting dose?

For many people the practical answer is to begin with whichever drug their clinician recommends and their plan covers, then switch if results or side effects fall short. Weight regain is common after stopping either medication, so a maintenance plan matters as much as the initial choice.

COMMON QUESTIONS

Frequently Asked Questions

Is tirzepatide or semaglutide better for weight loss?

In the SURMOUNT-5 head-to-head trial, tirzepatide produced about 20.2% average weight loss versus 13.7% for semaglutide over 72 weeks. Tirzepatide therefore has the stronger average result, but individual responses vary and insurance coverage often decides which drug a patient starts with.

Can you switch from semaglutide to tirzepatide?

Yes, switching is possible under medical supervision, usually starting at the lowest tirzepatide dose of 2.5 mg per week to limit side effects. Do not overlap the two drugs or stack doses without a clinician's guidance.

Is compounded tirzepatide as good as the brand-name version?

Compounded tirzepatide is not FDA-approved, is not reviewed for purity or potency, and is not guaranteed to match the brand product. The FDA advises using approved products when they are available, and many compounded sellers operate outside standard pharmacy oversight.